N/A
N=139
The Role of Circulating Soluble CD74 in Acute Lung Injury
Acute Lung Injury · Acute Respiratory Distress Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT02201446 ↗Enrolled (actual)
139
Serious AEs
10.1%
Results posted
Dec 2016
Primary outcome: Primary: Number of Participants Receiving Mechanical Ventilation — 51; NA participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult · 16+ yrs
- Sex
- All
- Sponsor
- Changhai Hospital
- Primary completion
- Nov 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Receiving Mechanical Ventilation |
51; NA | — |
| PRIMARY Fraction of Inspired Oxygen (FiO2)/Partial Arterial Oxygen Pressure (PO2) |
2.1; NA | — |
| PRIMARY Acute Physiology and Chronic Health Evaluation (APACHE) II Scores |
14.35; NA | — |
| PRIMARY Serum Soluble Cluster of Differentiations 74 (sCD74) |
132.92; -14.78 | — |
| PRIMARY Serum Soluble Cluster of Differentiations 74 (sCD74) |
132.92; -14.78 | — |
| SECONDARY Length of Stay in the ICU |
23; NA | — |
| SECONDARY Length of Hospital Stay |
36.94; NA | — |
| SECONDARY Days of Unassisted Ventilation |
22; NA | — |
| SECONDARY Death |
14; 0 | — |
| SECONDARY TNF-α |
138.67; NA | — |
| SECONDARY IL-6 |
305.36; NA | — |
| SECONDARY MIF |
129.27; NA | — |
Summary
Efforts to identify circulating factors that predict severity of acute lung injury/acute respiratory distress syndrome（ALI/ARDS） patients is unrevealing. The primary purpose of this study is to verify our hypothesis that soluble CD74 might be a potential novel ALI/ARDS biomarker.
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of ALI/ARDS
- Informed consent was obtained from either the subjects themselves or from designated surrogates before enrollment in the study.
Exclusion Criteria
- Patients who have chronic lung disease before enrollment.
- Patients who have severe organ dysfunction, autoimmune diseases and tumor.
- Women who are pregnant or breast-feeding.
- Patients who, in the opinion of the Investigator, have any other medical condition which renders the patient unable to complete the study or which would interfere with optimal participation in the study or produce significant risk to the patient.
- Patients participating in or planning to enroll in another clinical trial during the time of the study.
Data sourced from ClinicalTrials.gov (NCT02201446). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.